HepaRegeniX
| Invested since | 2016 |
| Based in | Baden-Württemberg |
About the company
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). A first compound has recently started clinical development.
MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
Do you want to
know more about this company?
More startups from Life Sciences
Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a …
cytena’s single-cell printer is a unique device for separating, sorting and handling of single biological cells. For the first time this method enables an automated, separation of single cells with …
smartbax is developing a new generation of antibiotics to address the increasing spread of multidrug-resistant bacteria. Their team of experts works on innovative solutions focusing on substances that simultaneously address …
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain …
NovaPump GmbH is developing and realising a leading solution for a novel right ventricular assist device (RVAD) with clear USPs (the only percutaneous device with pulsatile support). NovaPump’s catheter-based heart …
